Baseline serum levels of DCN-CS, a marker of ECM/collagen degradation, were also higher in those with metastatic disease as compared to those in healthy controls (p < 0.001), but there were no significant differences between those with metastatic and adjuvant disease. This evidence concerns the gene CS and metastatic neoplasm.